1. Academic Validation
  2. Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses

Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses

  • Sci Rep. 2020 Apr 14;10(1):6427. doi: 10.1038/s41598-020-63498-3.
Zhaohui Jiang 1 2 3 4 Lingyun Fu 1 2 3 4 Yini Xu 1 2 3 4 Xiaoxia Hu 1 2 3 4 Hong Yang 1 3 Yanyan Zhang 1 3 4 Hong Luo 1 3 4 Shiquan Gan 1 2 3 4 Ling Tao 1 3 Guiyou Liang 5 Xiangchun Shen 6 7 8 9
Affiliations

Affiliations

  • 1 The State Key Laboratory of Functions and Applications of Medicinal Plants, School of Basic Medical Sciences, Guizhou Medical University, University Town, Guian New District, 550025, Guizhou, China.
  • 2 The Department of Pharmacology of Materia Medica (The high efficacy application of natural medicinal resources engineering center of Guizhou Province and The high educational key laboratory of Guizhou province for natural medicianl Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, 550025, Guizhou, China.
  • 3 The key laboratory of optimal Utilizaiton of Natural Medicine Resources (The union key laboratory of Guiyang City-Guizhou Medical Univeristy), School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, 550025, Guizhou, China.
  • 4 The key laboratory of Endemic and Ethnic diseases of Ministry of Education, Guizhou Medical University, 550004, Guizhou, China.
  • 5 The State Key Laboratory of Functions and Applications of Medicinal Plants, School of Basic Medical Sciences, Guizhou Medical University, University Town, Guian New District, 550025, Guizhou, China. [email protected].
  • 6 The State Key Laboratory of Functions and Applications of Medicinal Plants, School of Basic Medical Sciences, Guizhou Medical University, University Town, Guian New District, 550025, Guizhou, China. [email protected].
  • 7 The Department of Pharmacology of Materia Medica (The high efficacy application of natural medicinal resources engineering center of Guizhou Province and The high educational key laboratory of Guizhou province for natural medicianl Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, 550025, Guizhou, China. [email protected].
  • 8 The key laboratory of optimal Utilizaiton of Natural Medicine Resources (The union key laboratory of Guiyang City-Guizhou Medical Univeristy), School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, 550025, Guizhou, China. [email protected].
  • 9 The key laboratory of Endemic and Ethnic diseases of Ministry of Education, Guizhou Medical University, 550004, Guizhou, China. [email protected].
Abstract

Diabetic cardiomyopathy (DCM) is the principal cause of death in people with diabetes. However, there is currently no effective strategy to prevent the development of DCM. Although cyclovirobuxine D (CVB-D) has been widely used to treat multiple cardiovascular diseases, the possible beneficial effects of CVB-D on DCM remained unknown. The present aim was to explore the potential effects and underlying mechanisms of CVB-D on DCM. We explored the effects of CVB-D in DCM by using high fat high sucrose diet and streptozotocin-induced rat DCM model. Cardiac function and survival in rats with DCM were improved via the amelioration of oxidative damage after CVB-D treatment. Our data also demonstrated that pre-treatment with CVB-D exerted a remarkable cytoprotective effect against high glucose -or H2O2 -induced neonatal rat cardiomyocyte damage via the suppression of Reactive Oxygen Species accumulation and restoration of mitochondrial membrane potential; this effect was associated with promotion of Nrf2 nuclear translocation and its downstream antioxidative stress signals (NQO-1, Prdx1). Overall, the present data has provided the first evidence that CVB-D has potential therapeutic in DCM, mainly by activation of the Nrf2 signalling pathway to suppress oxidative stress. Our findings also have positive implications on the novel promising clinical applications of CVB-D.

Figures
Products